AlloNK plus anti-CD20 mAb treatment yields complete B-cell depletion in autoimmune patients.

AlloNK, a treatment for autoimmune disease, has been administered to 32 patients as of October 1, 2025. No cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was observed. All patients experienced consistent and complete B-cell depletion by Day 13. The company plans to share initial clinical response data and conduct FDA regulatory interactions for refractory rheumatoid arthritis in the first half of 2026.